Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12330MR)

This product GTTS-WQ12330MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12330MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6632MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ9380MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ13188MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ11868MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ12992MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ305MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ527MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ1153MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABP 215
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW